Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
A phase 2 trial of Iruplinalkib in Non-small-cell lung cancer, run by Pingping Song, now recruiting.
Overview
Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05765877 by Pingping Song, with 26 participants planned, started 2023-03-01 and due to reach its primary completion in 2027-03. Interventions recorded: WX-0593 Tablets. Conditions recorded: Non-Small Cell Lung Cancer(NSCLC).
Linked to the drug Iruplinalkib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
Shares Iruplinalkib, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Shares Iruplinalkib, Non-small-cell lung cancer and the tag pipeline.
- TrialAllogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialEfficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of DM005 in Patients With Advanced Solid Tumors
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialHC010 in First-line PD-L1 Positive Advanced NSCLC Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag pipeline.